

The image shows the Vaxin Inc. logo in white text on a dark red background. To the right of the logo is a collage of scientific images: a green and red protein structure, a grayscale micrograph of cells, and a colorful 3D molecular model.

# Vaxin Inc.

Contact:  
Bill Enright  
President & CEO  
Phone: 240-654-1450  
Email: [enright@vaxin.com](mailto:enright@vaxin.com)

## **FOR IMMEDIATE RELEASE**

### **DAVID BRAKE PH.D. TO JOIN VAXIN'S BOARD OF DIRECTORS**

**Gaithersburg, MD – February 6, 2013** – Vaxin Inc., a clinical stage vaccine development company today announced the appointment of David Brake Ph.D. to its Board of Directors.

“Vaxin has a long history of product development in animal health. It will be great to have someone with David’s expertise in this area joining our Board,” said David J. Drutz, MD, Vaxin’s Chairman. “Vaxin has significant ongoing collaborations with Drs. Henry Baker and Nancy Cox at Auburn University in the development of a vaccine to sterilize dogs and cats and with Dr. Haroldo Toro also at Auburn University in the development of influenza and other vaccines for poultry. We now have someone to help provide valuable product development and business insights on these initiatives.”

Dr. Brake has more than 22 years of research and development experience with a record of significant achievements in the biomedical field. His expertise and practical experience cover product concept to commercialization spanning multiple areas of infectious diseases (viral, bacterial, and parasitic), immunology, vaccinology, oncology, and oral vaccine delivery with a strong focus on veterinary medicine biological products. Dr. Brake is the founder and principle of BioQuest Associates, LLC a consulting firm focused on veterinary vaccine development, regulatory submissions and intellectual property review. He currently serves as a scientific consultant to the U.S. Department of Homeland Security Science and Technology.

Prior to starting BioQuest, Dr. Brake worked at Pfizer Animal Health where he held several scientific and management positions.

Dr. Brake received his Ph.D. in Immunology and Microbiology from Hahnemann Medical University (now Drexel College of Medicine) and completed a NIH Postdoctoral Fellowship in the Department of Molecular Genetics at SmithKline Beecham Pharmaceuticals. He has numerous patents and publications in peer reviewed journals to his credit.

## **About Vaxin:**

Vaxin Inc. is a clinical stage company, developing next generation vaccines to address significant public health and biodefense needs. Vaxin is focused on vaccines designed to protect people against influenza and anthrax infection using proprietary, patented technologies for intranasal delivery, and is also developing unique animal health vaccines including an *in ovo* vaccines for preventing influenza outbreaks in poultry populations and a vaccine to sterilize dogs and cats. Vaxin's vaccines are designed to provide a safe, effective, easily administered, rapidly manufactured, and cost-competitive alternative to currently marketed products. Vaxin's intranasally delivered, adenovirus-based vaccines have successfully completed pre-clinical development, Investigational New Drug (IND) review and Phase 1 clinical studies of NasoVAX for seasonal and pre-pandemic influenza indications, demonstrating both proof-of-concept in man and providing an initial safety assessment of the technology platform. The proposed vectored anthrax vaccine product, AdVAV, is identical in route of administration, structure and manufacturing to these influenza candidates with the exception of the encoded antigen (*Bacillus anthracis* PA rather than *influenza virus* HA). It is expected that a nasal anthrax vaccine would greatly boost vaccine coverage against a bioterrorist attack during a crisis, and significantly reduce adverse side effects when compared to those induced by systemically-delivered anthrax vaccines. Vaxin recently received a multi-million dollar BARDA contract to advance this vaccine through Phase 1 clinical studies should the contract option be exercised.

## **Forward-looking statements:**

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

# # #